Samsung Biologics, Amgen and Biocon invest in US pharma sites

URLhttps://www.manufacturingdive.com/news/samsung-bio
SourceManufacturing Dive
Date Published09/15/2025
Author NameNathan Owens

Additional Reshoring Information:

Company/Division name Samsung Biologics
Parent companySamsung Biologics
Type of work Manufacturing
Reshoring category:Foreign Direct Investment
Year reshoring announced:2025
Capital investment ($):1,300
Country(ies) from which reshored:Korea, South
If relevant, work nearshored to:-
Industry(ies):Chemicals
Product(s) reshoredBiopharmaceuticals
What non-domestic negative factors made offshoring less attractive?Tariffs, Total cost
Find Reshoring Articles